NUTRITION AND ANABOLIC INTERVENTIONS IN CANCER CACHEXIA

癌症恶病质的营养和合成代谢干预

• 批准号: 7952173
• 负责人: Melinda Sheffield-Moore
• 金额: $ 0.24万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952173
• 关键词: Aftercare; Cachexia; Cervix carcinoma; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; DEXA; Diet Records; Funding; Goals; Grant; Institution; Intervention; Magnetic Resonance Imaging; Malignant Neoplasms; Molecular; Moods; Muscle; Muscle Proteins; Patients; Property; Protein Biosynthesis; Proteolysis; Quality-of-Life Assessment; Recurrence; Research; Research Personnel; Resources; Series; Skeletal Muscle; Source; Testing; Testosterone; United States National Institutes of Health; base; cancer type; chemotherapy; effective therapy; improved; muscle form; muscle strength; nutrition; protein degradation; stable isotope; wasting

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Worldwide, it is estimated that approximately 2 million people will die annually due to the consequences of cancer-related cachexia (muscle wasting). New targeted anabolic therapies aimed at improving lean body mass are clearly needed. Our hypothesis is that testosterone's anabolic properties will enhance lean muscle mass in patients with recurrent cervical carcinoma by increasing muscle protein synthesis and by inhibiting the activation of muscle proteolysis. Our goals are to determine the mechanisms underlying the cancer-induced loss of skeletal muscle protein and examine whether testosterone treatment can overcome the influence of these molecular factors. All subjects will perform a monthly DEXA, MRI, muscle strength tests and a series of Mood and Quality of Life assessments (before treatment and after 1, 2, and 3 rounds of chemotherapy). All subjects will participate in a stable isotope study of their muscle protein turnover at baseline and again after the 3 rounds of chemotherapy. Additionally, subjects will complete food diaries and wear an ActiGraph accelerometer (ActiGraph, LLC) to assess activity levels each week. This study will allow us to better understand the mechanisms underlying the loss of muscle mass with cancer cachexia, which will serve as a basis to develop effective treatments for improving lean muscle mass in all types of cancer-related cachexia.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 据估计，全世界每年约有 200 万人因癌症相关恶病质（肌肉萎缩）的后果而死亡。显然需要旨在改善去脂体重的新的靶向合成代谢疗法。我们的假设是，睾酮的合成代谢特性将通过增加肌肉蛋白合成和抑制肌肉蛋白水解的激活来增强复发性宫颈癌患者的瘦肌肉质量。 我们的目标是确定癌症引起的骨骼肌蛋白丢失的机制，并检查睾酮治疗是否可以克服这些分子因素的影响。所有受试者将每月进行一次 DEXA、MRI、肌肉力量测试以及一系列情绪和生活质量评估（治疗前以及 1、2 和 3 轮化疗后）。所有受试者将在基线时以及 3 轮化疗后再次参加针对其肌肉蛋白周转率的稳定同位素研究。此外，受试者将完成饮食日记并佩戴 ActiGraph 加速计 (ActiGraph, LLC) 来评估每周的活动水平。这项研究将使我们能够更好地了解癌症恶病质导致肌肉质量损失的机制，这将成为开发有效治疗方法的基础，以改善所有类型的癌症相关恶病质中的瘦肌肉质量。